Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.6 BRL | +1.69% |
|
+0.15% | -18.22% |
May. 09 | Transcript : Dexco S.A., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Dexco S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company appears to be poorly valued given its net asset value.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company is in debt and has limited leeway for investment
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Forest & Wood Products
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-18.22% | 956M | A- | ||
+17.34% | 5.96B | B- | ||
+14.47% | 3.66B | B- | ||
-6.33% | 1.91B | C | ||
+3.17% | 1.34B | A- | ||
+16.93% | 1.18B | - | ||
-15.89% | 758M | B- | ||
-39.28% | 490M | - | ||
+39.54% | 496M | C | ||
-22.54% | 487M | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DXCO3 Stock
- Ratings Dexco S.A.